WO1993009437A3 - Nuclear matrix protein fluid assay - Google Patents

Nuclear matrix protein fluid assay

Info

Publication number
WO1993009437A3
WO1993009437A3 PCT/US1992/009220 US9209220W WO1993009437A3 WO 1993009437 A3 WO1993009437 A3 WO 1993009437A3 US 9209220 W US9209220 W US 9209220W WO 1993009437 A3 WO1993009437 A3 WO 1993009437A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
matrix
nuclear
disclosed
cells
method
Prior art date
Application number
PCT/US1992/009220
Other languages
French (fr)
Other versions
WO1993009437A2 (en )
Inventor
Lee Anne Beausang
Graham P Lidgard
Thomas E Miller
Original Assignee
Matritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/961Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se

Abstract

Disclosed is a method for detecting and quantitating soluble nuclear matrix proteins in body fluids and extracellular media. The method is useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of nuclear matrix proteins in soluble form from cells.
PCT/US1992/009220 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay WO1993009437A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US78580491 true 1991-10-31 1991-10-31
US785,804 1991-10-31

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP50855693A JP3190042B2 (en) 1991-10-31 1992-10-29 Nuclear matrix protein solution assay
EP19920925031 EP0642668B1 (en) 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay
CA 2122473 CA2122473C (en) 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay
DE1992630890 DE69230890D1 (en) 1991-10-31 1992-10-29 Determination of nuclear matrix proteins in fluids
DE1992630890 DE69230890T2 (en) 1991-10-31 1992-10-29 Determination of nuclear matrix proteins in fluids

Publications (2)

Publication Number Publication Date
WO1993009437A2 true WO1993009437A2 (en) 1993-05-13
WO1993009437A3 true true WO1993009437A3 (en) 1993-06-10

Family

ID=25136671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009220 WO1993009437A3 (en) 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay

Country Status (7)

Country Link
US (8) US5840503A (en)
EP (1) EP0642668B1 (en)
JP (1) JP3190042B2 (en)
CA (1) CA2122473C (en)
DE (2) DE69230890D1 (en)
ES (1) ES2147555T3 (en)
WO (1) WO1993009437A3 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009437A3 (en) * 1991-10-31 1993-06-10 Matritech Inc Nuclear matrix protein fluid assay
DE69333377D1 (en) * 1992-06-22 2004-02-12 Matritech Inc Novel marker of malignant cell types in the inner nuclear matrix
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
WO1997016206A8 (en) * 1995-11-03 1999-08-05 Robert R Bahnson Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders
US6280956B1 (en) 1995-11-03 2001-08-28 University Of Pittsburgh Antibodies to bladder cancer nuclear matrix proteins and their use
US5914238A (en) 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6232443B1 (en) * 1997-04-08 2001-05-15 University Of Pittsburgh Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
JP3517642B2 (en) * 1998-03-18 2004-04-12 ロシュ ダイアグノスティックス ゲーエムベーハー Detection of apoptosis product
US7229772B1 (en) 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products
DE60035499T2 (en) 1999-05-17 2008-03-20 Cytyc Corp., Marlborough Identification of material from the milk duct of the breast
US6617432B1 (en) 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
US20030228640A1 (en) * 1999-10-15 2003-12-11 University Of Pittsburgh Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US7012335B2 (en) 2000-02-22 2006-03-14 Samsung Electronics Co., Ltd. Semiconductor device wiring and method of manufacturing the same
US7654227B1 (en) * 2001-12-20 2010-02-02 Pat Yananton Absorbent pad for entrapping small and large particles, retaining liquids and eliminating odors
US7080373B2 (en) * 2001-03-07 2006-07-18 Freescale Semiconductor, Inc. Method and device for creating and using pre-internalized program files
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
JP4274856B2 (en) * 2003-06-19 2009-06-10 オリンパス株式会社 Method for detecting a reaction between Dna and dna-binding protein
JP4425919B2 (en) * 2003-09-23 2010-03-03 エヌエックスピー ビー ヴィNxp B.V. Adaptive filter
US7649988B2 (en) 2004-06-15 2010-01-19 Acoustic Technologies, Inc. Comfort noise generator using modified Doblinger noise estimate
JP5073491B2 (en) * 2004-07-19 2012-11-14 プロテインシンプル The method for the detection of an analyte
US7846676B2 (en) * 2004-07-19 2010-12-07 Cell Biosciences, Inc. Methods and devices for analyte detection
US7935479B2 (en) * 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
US8021611B2 (en) * 2005-04-09 2011-09-20 ProteinSimple Automated micro-volume assay system
CA2608750A1 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
WO2007035864A3 (en) 2005-09-20 2007-11-22 Cell Biosciences Inc Electrophoresis standards, methods and kits
US20080017512A1 (en) * 2006-07-24 2008-01-24 Bordunov Andrei V Coatings for capillaries capable of capturing analytes
WO2008057605A3 (en) * 2006-11-10 2008-07-17 Mike Helms Nuclear protein extraction medium and method of use
US20090023156A1 (en) * 2007-07-20 2009-01-22 Voss Karl O Methods and reagents for quantifying analytes
JP2011206049A (en) * 2010-03-08 2011-10-20 Sumio Sugano Necrosis marker and use thereof
WO2013155634A1 (en) 2012-04-19 2013-10-24 Jiaqi Wu Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003910A1 (en) * 1985-12-24 1987-07-02 Massachusetts Institute Of Technology Cellular method for determining tissue of origin
WO1989006697A1 (en) * 1988-01-19 1989-07-27 The University Of Sydney Detection of cell death

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4937185A (en) * 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US5017474A (en) * 1988-02-12 1991-05-21 Eastman Kodak Company Wash solution, test kit and method for the determination of an immunological ligand
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
EP0527941B1 (en) * 1990-05-01 1996-09-18 Isis Pharmaceuticals, Inc. Identification of novel drugs and reagents
WO1993009437A3 (en) * 1991-10-31 1993-06-10 Matritech Inc Nuclear matrix protein fluid assay
DE69333377D1 (en) * 1992-06-22 2004-02-12 Matritech Inc Novel marker of malignant cell types in the inner nuclear matrix

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003910A1 (en) * 1985-12-24 1987-07-02 Massachusetts Institute Of Technology Cellular method for determining tissue of origin
WO1989006697A1 (en) * 1988-01-19 1989-07-27 The University Of Sydney Detection of cell death

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CELL BIOLOGY vol. 115, no. 3, 1991, NEW YORK NY US page 314A T. E. MILLER ET AL. 'Release of Nuclear Matrix Proteins during Apoptotic Cell Death' *
JOURNAL OF UROLOGY vol. 143, no. 4, April 1990, BALTIMORE MD US page 227A H. GETZENBERG AND DONALD S. COFFEY 'Tissue Specifity and Cell Death Are Associated with Specific Alterations in Nuclear Matrix Proteins' *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 85, no. 1, January 1988, WASHINGTON US pages 121 - 125 EDWARD G. FEY AND SHELDON PENMAN 'Nuclear Matrix Proteins Reflect Cell Type of Origin in Cultured Human Cells' *

Also Published As

Publication number Publication date Type
US20060127941A1 (en) 2006-06-15 application
DE69230890D1 (en) 2000-05-11 grant
JP3190042B2 (en) 2001-07-16 grant
CA2122473A1 (en) 1993-05-13 application
US5965376A (en) 1999-10-12 grant
US5989826A (en) 1999-11-23 grant
ES2147555T3 (en) 2000-09-16 grant
US20030096304A1 (en) 2003-05-22 application
DE69230890T2 (en) 2000-12-07 grant
US5840503A (en) 1998-11-24 grant
JPH07500671A (en) 1995-01-19 application
US6410247B1 (en) 2002-06-25 grant
CA2122473C (en) 2001-01-23 grant
EP0642668B1 (en) 2000-04-05 grant
US20050059026A1 (en) 2005-03-17 application
US6740494B2 (en) 2004-05-25 grant
EP0642668A1 (en) 1995-03-15 application
US6162608A (en) 2000-12-19 grant
WO1993009437A2 (en) 1993-05-13 application

Similar Documents

Publication Publication Date Title
Postlethwaite et al. The chemotactic attraction of human fibroblasts to a lymphocyte-derived factor.
Papageorgiou et al. Production and characterization of migration inhibitory factor (s)(MIF) of established lymphoid and non-lymphoid cell lines
French et al. Culture media for Pseudomonas solanacearum isolation, identification and maintenance
Domenicucci et al. Characterization of porcine osteonectin extracted from foetal calvariae
Bignold Measurement of chemotaxis of polymorphonuclear leukocytes in vitro: The problems of the control of gradients of chemotactic factors, of the control of the cells and of the separation of chemotaxis from chemokinesis
Siegel et al. Evaluation of the Human Sperm Proacrosin-Acrosin System Using Gelatin-Sodium Dodecyl Sulfate-Polyacrylam ide Gel Electrophesis
Adams et al. Development and use of monoclonal antibody probes forimmunohistochemistry, ELISA and IFAT to detect bacterial and parasitic fish pathogens
Seki et al. Isolation of oligomycin-sensitive adenosine triphosphatase from beef heart mitochondria and analysis of its fine structure
Kantor et al. Action of Escherichia coli enterotoxin: adenylate cyclase behavior of intestinal epithelial cells in culture
Harris Effect of hyperbaric oxygen on leucocyte lysosomes
Kirkpatrick Lesbians as parents.
Vallely et al. The identification of factors in seminal plasma responsible for suppression of natural killer cell activity.
Kaw et al. Reaction of cells cultured in vitro to different asbestos dusts of equal surface area but different fibre length.
Ishihara et al. The blastocoelic fluid of sea urchin embryo induces exogastrulation
AVITABILE et al. Comparison of system characteristics using various model reduction techniques
JPS6028934A (en) Cell differentiation introduction substance
WO1998026277A3 (en) Apparatus and method for detecting and identifying infectious agents
JPH0246280A (en) Device for enhancing fluorescence and reaction rate and its use
Brown et al. Combined plasmid and peptide analysis of clinical and environmental Legionella pneumophila strains associated with a small cluster of Legionnaires' disease cases
Neilson et al. Kinetics of circulating TNF-α and TNF soluble receptors following surgery in a clinical model of sepsis
JPS62227352A (en) Living body prosthetic heart valve and method and apparatus for producing the same
WO1997005248A3 (en) Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins
Butcher Understanding abnormal behavior across cultures: The use of objective personality assessment methods.
Ripe et al. MOULD ALLKRGY: III. Extract preparation of moulds
Schremmer-Danninger et al. Autoradiographic visualization of B 1 bradykinin receptors in porcine vascular tissues in the presence or absence of inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2122473

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2122473

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1992925031

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992925031

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992925031

Country of ref document: EP